Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0793
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2636
    +0.0013 (+0.11%)
     
  • USD/JPY

    151.2130
    -0.1590 (-0.11%)
     
  • Bitcoin USD

    69,140.48
    -1,921.55 (-2.70%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

FDA panel says Cubist anti-infective shows efficacy, safety

March 31 (Reuters) - Cubist Pharmaceuticals Inc's anti-infective tedizolid for acute bacterial skin infections shows substantial evidence of safety and efficacy, an advisory panel to the U.S. Food and Drug Administration concluded on Monday.

The panel's vote was unanimous. The FDA is not obliged to follow the advice of its expert panels but typically does so.

(Reporting by Toni Clarke in Washington; Editing by Bill Trott)

Advertisement